<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01222104</url>
  </required_header>
  <id_info>
    <org_study_id>0903</org_study_id>
    <nct_id>NCT01222104</nct_id>
  </id_info>
  <brief_title>Angio-Seal Interventional Radiology (IR) Registry</brief_title>
  <official_title>Clinical Registry of St. Jude Medical Angio-Seal™ Vascular Closure Devices Following Interventional Radiology Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect data on the standard of care use of the St. Jude
      Medical (SJM) Angio Seal™ Evolution™ and V-Twist Integrated Platform (VIP) Devices in
      diagnostic and/or interventional radiology patient populations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Major Vascular Complications</measure>
    <time_frame>30 days</time_frame>
    <description>Collect data on patients who have undergone a diagnostic and/or interventional radiology procedure in which the St. Jude Medical (SJM) Angio-Seal Evolution or V-Twist Integrated Platform (VIP) Device was deployed, to evaluate the rate of major vascular complications out to 30 days post-procedure.
The following are defined as a major vascular complication:
Vascular injury requiring repair via surgery, angioplasty, ultrasound guided compression, thrombin injection, or other means;
Permanent (unresolved at 30-day post-procedure evaluation) access site-related nerve injury or access site-related nerve injury requiring intervention;
Access site related bleeding requiring transfusion;
New ipsilateral lower extremity ischemia requiring surgical intervention;
Retroperitoneal bleeding;
Generalized infection requiring prolonged hospitalization and/or treatment with IV antibiotics;
Access related complication that results in extended hospital stay;
Death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Hemostasis</measure>
    <time_frame>Procedure</time_frame>
    <description>Time-to-hemostasis stratified into 3 categories: hemostasis in less than 1 minute alone or in combination with manual compression (standard of care), 1-5 minutes alone or in combination with manual compression (standard of care), and/or hemostasis achieved &gt;5 minutes and/or with additional hemostasis methods required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Minor Vascular Complications</measure>
    <time_frame>30 days</time_frame>
    <description>The following are defined as a minor vascular complication:
Unanticipated access site bleeding requiring ≥ 30 minutes of manual compression to re-achieve hemostasis;
Ipsilateral hematoma &gt;10 cm;
Ipsilateral pseudoaneurysm without intervention;
Ipsilateral arteriovenous fistula;
Ipsilateral deep vein thrombosis;
Local access site infection without prolonged hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Guided Access on Use of Closure Device.</measure>
    <time_frame>30 days</time_frame>
    <description>The influence of fluoroscopy and/or ultrasound guided access on the decision to use a closure device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Guided Access on Achieving Target Puncture Location.</measure>
    <time_frame>30 days</time_frame>
    <description>The influence of fluoroscopy and/or ultrasound guided access on puncture location.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Major Vascular Complications (MVCs) by Guided Access Mode.</measure>
    <time_frame>30 days</time_frame>
    <description>The influence of fluoroscopy and/or ultrasound guided access on Major Vascular Complications (MVCs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Minor Vascular Complications by Guided Access Mode.</measure>
    <time_frame>30 days</time_frame>
    <description>The influence of fluoroscopy and/or ultrasound guided access on minor vascular complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Peripheral Vascular Disease (PVD) on Use of Closure Device</measure>
    <time_frame>30 days</time_frame>
    <description>Presence of peripheral vascular disease (PVD) and its effect on the decision to use a closure device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Peripheral Vascular Disease (PVD) on Achieving Hemostasis by Device</measure>
    <time_frame>30 days</time_frame>
    <description>Presence of peripheral vascular disease (PVD) and its effect on hemostasis. Initial hemostasis by device achieved.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Major Vascular Complications (MVC) by Presence of Peripheral Vascular Disease (PVD)</measure>
    <time_frame>30 days</time_frame>
    <description>Presence of peripheral vascular disease (PVD) and its effect on Major Vascular Complications (MVC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Minor Vascular Complications by Presence of Peripheral Vascular Disease (PVD)</measure>
    <time_frame>30 days</time_frame>
    <description>Presence of peripheral vascular disease (PVD) and its effect on minor vascular complications.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">634</enrollment>
  <condition>Diagnostic and/or Interventional Radiology Procedures</condition>
  <arm_group>
    <arm_group_label>Angio-Seal</arm_group_label>
    <description>Angio-Seal attempted and/or deployed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Not deployed</arm_group_label>
    <description>Other method of closure</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who undergo a diagnostic and/or interventional radiology procedure through
        percutaneous femoral artery access and meet the registry selection criteria.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is undergoing a diagnostic and/or interventional radiology procedure via
             femoral arterial access and the investigator performing the procedure would use
             Angio-Seal for closure as part of his/her routine care of the patient. Angio-Seal
             deployment will follow the standard of care for vascular closure device use and the
             Instructions for Use (IFU) for the device.

          2. Sheath angiography prior to Angio-Seal deployment reveals appropriate anatomy and
             puncture location for vascular closure device deployment.

        Exclusion Criteria:

        1. Patients who are unable to provide written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zoltan Turi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cooper University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Cardiac and Vascular Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaleida Health</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayfield Clinic, Inc.; The University Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2010</study_first_submitted>
  <study_first_submitted_qc>October 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2010</study_first_posted>
  <results_first_submitted>April 28, 2014</results_first_submitted>
  <results_first_submitted_qc>November 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 19, 2014</results_first_posted>
  <last_update_submitted>December 15, 2014</last_update_submitted>
  <last_update_submitted_qc>December 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vascular closure</keyword>
  <keyword>Angio-Seal</keyword>
  <keyword>Interventional radiology</keyword>
  <keyword>femoral artery</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="634"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Angio-Seal Deployment Attempted</title>
              <participants_list>
                <participants group_id="P1" count="534"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Successful Deployment</title>
              <participants_list>
                <participants group_id="P1" count="529"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Successful Deployment and Hemostasis</title>
              <participants_list>
                <participants group_id="P1" count="524"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 30-day Visit-Angio-Seal</title>
              <participants_list>
                <participants group_id="P1" count="497"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 30-day Visit-No Angio-Seal</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="587"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="634"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.6" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Major Vascular Complications</title>
        <description>Collect data on patients who have undergone a diagnostic and/or interventional radiology procedure in which the St. Jude Medical (SJM) Angio-Seal Evolution or V-Twist Integrated Platform (VIP) Device was deployed, to evaluate the rate of major vascular complications out to 30 days post-procedure.
The following are defined as a major vascular complication:
Vascular injury requiring repair via surgery, angioplasty, ultrasound guided compression, thrombin injection, or other means;
Permanent (unresolved at 30-day post-procedure evaluation) access site-related nerve injury or access site-related nerve injury requiring intervention;
Access site related bleeding requiring transfusion;
New ipsilateral lower extremity ischemia requiring surgical intervention;
Retroperitoneal bleeding;
Generalized infection requiring prolonged hospitalization and/or treatment with IV antibiotics;
Access related complication that results in extended hospital stay;
Death</description>
        <time_frame>30 days</time_frame>
        <population>5 subjects underwent vascular closure with Angio-Seal on right and left sides.</population>
        <group_list>
          <group group_id="O1">
            <title>Angio -Seal</title>
            <description>Angio-Seal attempted and/or deployed group</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Major Vascular Complications</title>
          <description>Collect data on patients who have undergone a diagnostic and/or interventional radiology procedure in which the St. Jude Medical (SJM) Angio-Seal Evolution or V-Twist Integrated Platform (VIP) Device was deployed, to evaluate the rate of major vascular complications out to 30 days post-procedure.
The following are defined as a major vascular complication:
Vascular injury requiring repair via surgery, angioplasty, ultrasound guided compression, thrombin injection, or other means;
Permanent (unresolved at 30-day post-procedure evaluation) access site-related nerve injury or access site-related nerve injury requiring intervention;
Access site related bleeding requiring transfusion;
New ipsilateral lower extremity ischemia requiring surgical intervention;
Retroperitoneal bleeding;
Generalized infection requiring prolonged hospitalization and/or treatment with IV antibiotics;
Access related complication that results in extended hospital stay;
Death</description>
          <population>5 subjects underwent vascular closure with Angio-Seal on right and left sides.</population>
          <units>Percentage of Procedures</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="534"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="539"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Hemostasis</title>
        <description>Time-to-hemostasis stratified into 3 categories: hemostasis in less than 1 minute alone or in combination with manual compression (standard of care), 1-5 minutes alone or in combination with manual compression (standard of care), and/or hemostasis achieved &gt;5 minutes and/or with additional hemostasis methods required.</description>
        <time_frame>Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Angio-Seal</title>
            <description>Secondary outcome reported in subjects with successful Angio-Seal deployment which achieved hemostasis by device.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Hemostasis</title>
          <description>Time-to-hemostasis stratified into 3 categories: hemostasis in less than 1 minute alone or in combination with manual compression (standard of care), 1-5 minutes alone or in combination with manual compression (standard of care), and/or hemostasis achieved &gt;5 minutes and/or with additional hemostasis methods required.</description>
          <units>% of procedures</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="524"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="529"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemostasis less than 1 minute</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemostasis between 1-5 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemostasis greater than 5 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Minor Vascular Complications</title>
        <description>The following are defined as a minor vascular complication:
Unanticipated access site bleeding requiring ≥ 30 minutes of manual compression to re-achieve hemostasis;
Ipsilateral hematoma &gt;10 cm;
Ipsilateral pseudoaneurysm without intervention;
Ipsilateral arteriovenous fistula;
Ipsilateral deep vein thrombosis;
Local access site infection without prolonged hospitalization</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
          </group>
        </group_list>
        <measure>
          <title>Rate of Minor Vascular Complications</title>
          <description>The following are defined as a minor vascular complication:
Unanticipated access site bleeding requiring ≥ 30 minutes of manual compression to re-achieve hemostasis;
Ipsilateral hematoma &gt;10 cm;
Ipsilateral pseudoaneurysm without intervention;
Ipsilateral arteriovenous fistula;
Ipsilateral deep vein thrombosis;
Local access site infection without prolonged hospitalization</description>
          <units>% of procedures with minor vasc comp.</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="534"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="539"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of Guided Access on Use of Closure Device.</title>
        <description>The influence of fluoroscopy and/or ultrasound guided access on the decision to use a closure device.</description>
        <time_frame>30 days</time_frame>
        <population>Percentage of procedures with devices deployed</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>All enrolled participants</description>
          </group>
        </group_list>
        <measure>
          <title>Impact of Guided Access on Use of Closure Device.</title>
          <description>The influence of fluoroscopy and/or ultrasound guided access on the decision to use a closure device.</description>
          <population>Percentage of procedures with devices deployed</population>
          <units>% of procedures using a closure device</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="634"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="639"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ultrasound only, n=30 procedures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fluorscopy only, n=309 procedures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fluoro and ultrasound, n=144 procedures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither fluoro nor ultrasound, n=156 procedures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of Guided Access on Achieving Target Puncture Location.</title>
        <description>The influence of fluoroscopy and/or ultrasound guided access on puncture location.</description>
        <time_frame>30 days</time_frame>
        <population>Deployed subjects with readable angiograms</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants With Deployments and Readable Angiograms</title>
          </group>
        </group_list>
        <measure>
          <title>Impact of Guided Access on Achieving Target Puncture Location.</title>
          <description>The influence of fluoroscopy and/or ultrasound guided access on puncture location.</description>
          <population>Deployed subjects with readable angiograms</population>
          <units>% within target zone</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ultrasound only, n=23 participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fluoroscopy only, n=240 participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Both Fluoro and ultrasound, n=113 participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither fluoro nor ultrasound, n=92 participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Major Vascular Complications (MVCs) by Guided Access Mode.</title>
        <description>The influence of fluoroscopy and/or ultrasound guided access on Major Vascular Complications (MVCs).</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Participants With Deployments</title>
            <description>Participants with successful or attempted Angio-Seal deployments</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Major Vascular Complications (MVCs) by Guided Access Mode.</title>
          <description>The influence of fluoroscopy and/or ultrasound guided access on Major Vascular Complications (MVCs).</description>
          <units>% of procedures with MVCs</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="534"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="539"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ultrasound only, n=27 procedures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fluoroscopy only, n=269 procedures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fluoro and ultrasound, n=128 procedures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither fluoro nor ultrasound, n=115 procedures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Minor Vascular Complications by Guided Access Mode.</title>
        <description>The influence of fluoroscopy and/or ultrasound guided access on minor vascular complications.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Participants With Deployments</title>
            <description>Participants with successful or attempted Angio-Seal deployments</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Minor Vascular Complications by Guided Access Mode.</title>
          <description>The influence of fluoroscopy and/or ultrasound guided access on minor vascular complications.</description>
          <units>% of procedures with minor vasc comp.</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="534"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="539"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ultrasound only, n=27 procedures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fluoroscopy only, n=269 procedures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fluoro and ultrasound, n=128 procedures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither fluoro nor ultrasound, n=115 procedures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of Peripheral Vascular Disease (PVD) on Use of Closure Device</title>
        <description>Presence of peripheral vascular disease (PVD) and its effect on the decision to use a closure device</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
          </group>
        </group_list>
        <measure>
          <title>Impact of Peripheral Vascular Disease (PVD) on Use of Closure Device</title>
          <description>Presence of peripheral vascular disease (PVD) and its effect on the decision to use a closure device</description>
          <units>% of procedures using closure device</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="634"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="639"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-PVD procedures, n=248</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PVD procedures, n=391</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of Peripheral Vascular Disease (PVD) on Achieving Hemostasis by Device</title>
        <description>Presence of peripheral vascular disease (PVD) and its effect on hemostasis. Initial hemostasis by device achieved.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Participants With Deployments</title>
            <description>Participants with successful or attempted Angio-Seal deployments</description>
          </group>
        </group_list>
        <measure>
          <title>Impact of Peripheral Vascular Disease (PVD) on Achieving Hemostasis by Device</title>
          <description>Presence of peripheral vascular disease (PVD) and its effect on hemostasis. Initial hemostasis by device achieved.</description>
          <units>% of procedures achieving hemostasis</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="534"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="539"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-PVD procedures, n=232</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PVD procedures, n=307</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Major Vascular Complications (MVC) by Presence of Peripheral Vascular Disease (PVD)</title>
        <description>Presence of peripheral vascular disease (PVD) and its effect on Major Vascular Complications (MVC).</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Participants With Deployments</title>
            <description>Participants with successful or attempted Angio-Seal deployments</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Major Vascular Complications (MVC) by Presence of Peripheral Vascular Disease (PVD)</title>
          <description>Presence of peripheral vascular disease (PVD) and its effect on Major Vascular Complications (MVC).</description>
          <units>% of procedures with MVCs</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="534"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="539"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-PVD procedures, n=232</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PVD procedures, n=307</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Minor Vascular Complications by Presence of Peripheral Vascular Disease (PVD)</title>
        <description>Presence of peripheral vascular disease (PVD) and its effect on minor vascular complications.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Participants With Deployment</title>
            <description>Participants with successful or attempted Angio-Seal deployments</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Minor Vascular Complications by Presence of Peripheral Vascular Disease (PVD)</title>
          <description>Presence of peripheral vascular disease (PVD) and its effect on minor vascular complications.</description>
          <units>% of procedures with minor vasc comp.</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="534"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="539"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-PVD procedures, n=232</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PVD procedures, n=307</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="634"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Retroperitoneal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="634"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="634"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular injury requiring repair via surgery or other means</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="634"/>
              </event>
              <event>
                <sub_title>New ipsilateral lower extremity ischemia requiring intervention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="634"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="634"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Ipsilateral hematoma &gt;10cm</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="634"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Major and minor vascular complications were collected as Serious Adverse Event and Other Adverse Events as defined in the protocol.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Andrew Campbell</name_or_title>
      <organization>St Jude Medical</organization>
      <phone>651-756-5538</phone>
      <email>acampbell2@sjm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

